SCHEMBL21267538

SCHEMBL21267538

CCC(C)N1CC(C)(C)Oc2c(F)cc(-c3nc(Nc4ccc(CN5CCC(C(C)(C)O)CC5)cn4)ncc3F)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK6 Q00534 19/20 0.58
▸ CDK4 P11802 15/20 0.58
▸ CCNA2 P20248 7/20 0.58
▸ CDK2 P24941 6/20 0.58
▸ CSF1R P07333 5/20 0.58
▸ CCND3 P30281 10/20 0.47
▸ CDK1 P06493 5/20 0.47
▸ CCND1 P24385 5/20 0.47
▸ CCNE2 O96020 3/20 0.47
▸ CCNK O75909 2/20 0.47
▸ CDK9 P50750 2/20 0.47
▸ CIT O14578 1/20 0.47
▸ GAK O14976 1/20 0.47
▸ DYRK3 O43781 1/20 0.47
▸ CCNT1 O60563 1/20 0.47
▸ STK16 O75716 1/20 0.47
▸ STK10 O94804 1/20 0.47
▸ PRKD3 O94806 1/20 0.47
▸ ABCB11 O95342 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21267353 0.94 CDK6 (0.62) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267582 0.90 CDK6 (0.71) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267930 0.89 CDK6 (0.57) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267357 0.88 CDK6 (0.57) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267590 0.83 CDK6 (0.62) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267540 0.82 CDK6 (0.51) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267530 0.82 CDK6 (0.63) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267617 0.81 CDK6 (0.53) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267232 0.81 CDK4 (0.52) CDK6CDK4CCNA2CDK2CSF1R
SCHEMBL21267880 0.80 CDK6 (0.52) CDK6CDK4CCNA2CDK2CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174252-B2 Heterocyclic compounds as kinase inhibitors CDK6, CDK4, CDK9 CDK6 1/4885CDK4 2/4885CCNA2 33/4885
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 CDK6 2/4885CDK4 1/4885CCNA2 38/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 CDK6 2/4885CDK4 1/4885CCNA2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback